Genomics England Limited (Genomics England) will move its headquarters to Canary Wharf this autumn, as part of the development of a major life science cluster.
The move for Genomics England, one of the world’s most cutting-edge life science organisations, follows the recent announcement that CWG and Kadans Science Partner formed a joint venture to develop a 750,000 sq ft commercial laboratory building, the largest in Europe.
Genomics England will move into One Canada Square, giving the company a world-class platform for growth and collaboration in developing life sciences community at Canary Wharf.
Canary Wharf is already home to a number of leading healthcare and life sciences-focused organisations, including: Barts Health NHS Trust, the Medicines and Healthcare Products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation.
Shobi Khan, CEO of Canary Wharf Group, said: “Securing a company of Genomics England’s stature is a significant endorsement of our vision to establish Canary Wharf as a world class life sciences hub in the UK.”
“Canary Wharf offers Genomics England an unrivalled and exceptional working environment with access to great transport, power and cloud infrastructure, more than 300 shops and restaurants, 20 acres of green spaces and 5 km of waterside boardwalks.”
“Attracting a cluster of innovative companies to Canary Wharf, in advance of opening our purpose-built laboratory enabled space at North Quay, is part of our strategy to make Canary Wharf one of the UK’s leading centres for life sciences.”
Chris Wigley, CEO of Genomics England Limited, said: “Genomics England is delivering an ambitious agenda, in partnership with the NHS and others, that will ensure the UK continues to lead the world in genomics. The move to Canary Wharf will enable us to deliver this agenda more effectively, benefitting our workforce as well as moving us to a more modern estate in close proximity to our partners in the NHS and Life Sciences sector.”
Genomics England is a global leader in advancing and delivering genomic medicine and genomic research. Its work is transforming science into cutting edge healthcare and enabling the world’s first national Whole Genome Sequencing service in the NHS Genomic Medicine Service, to deliver the most advanced genomic healthcare to patients today.
It helps researchers use the data to help find the causes of diseases and to work on new treatments and is at the cutting edge of global research into the human genome. Genomics England is regarded as one of the most valuable organisations of the UK’s life science sector.
Canary Wharf Group was advised by CBRE and JLL, SHB Real Estate acted for Genomics England.
For further information, please contact:
Canary Wharf Group plc
T: 020 7418 2166